SCHEMBL170928

SCHEMBL170928

CC[C@H](N)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.56
LMNA P02545 1/20 0.52
SCN4A P35499 7/20 0.50
DPP4 P27487 2/20 0.50
F2 P00734 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43945 1.00 SLC6A4 (0.56) SLC6A4LMNASCN4ADPP4F2
SCHEMBL29503095 1.00 SLC6A4 (0.56) SLC6A4LMNASCN4ADPP4F2
SCHEMBL176808 1.00 SLC6A4 (0.56) SLC6A4LMNASCN4ADPP4F2
Benzene SCHEMBL28170835 1.00 SLC6A4 (0.56) SLC6A4LMNASCN4ADPP4F2
SCHEMBL28382272 0.97 SLC6A4 (0.54) SLC6A4LMNASCN4ADPP4F2
Iodide SCHEMBL6672339 0.97 SLC6A4 (0.54) SLC6A4LMNASCN4ADPP4F2
Hydrochloric Acid SCHEMBL7185884 0.97 SLC6A4 (0.54) SLC6A4LMNASCN4ADPP4F2
Hydrochloric Acid SCHEMBL5945406 0.97 SLC6A4 (0.54) SLC6A4LMNASCN4ADPP4F2
Hydrochloric Acid SCHEMBL6852974 0.97 SLC6A4 (0.54) SLC6A4LMNASCN4ADPP4F2
Hydrochloric Acid SCHEMBL1607928 0.97 SLC6A4 (0.54) SLC6A4LMNASCN4ADPP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 937 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250078176-A1 ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS BASF SE (DE) 2025-03-06 US claimed
CN-119119035-A RIPK1 kinase target inhibitor and preparation method and application thereof 中山大学 2024-12-13 CN claimed
CN-118946165-A Interface interaction spin-photon conversion body heterostructure and preparation method 武汉大学 2024-11-12 CN claimed
CN-118745344-A Perovskite circular polarization luminescent material with chiral low-dimensional-three-dimensional heterojunction structure and application thereof 武汉大学 2024-10-08 CN claimed
CN-118435582-A Environmental attributes of nitrogen-containing chemicals 巴斯夫欧洲公司 2024-08-02 CN claimed
CN-115515957-B Stereoselective synthesis of intermediates for the preparation of heterocyclic compounds 太景生物科技股份有限公司 2024-06-25 CN claimed
CN-115667222-B Method for preparing GLP-1 receptor agonist 杭州中美华东制药有限公司 2023-09-29 CN claimed
WO-2023117926-A1 ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS BASF SE (DE) 2023-06-29 WO claimed
EP-4157841-A1 STEREOSELECTIVE SYNTHESIS OF INTERMEDIATE FOR PREPARATION OF HETEROCYCLIC COMPOUND Taigen Biotechnology Co., Ltd. (TW) 2023-04-05 EP claimed
US-20230048657-A1 PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE HOFFMANN-LA ROCHE INC. (US) 2023-02-16 US claimed
US-6780875-B2 RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS SMITHKLINE BEECHAM S.P.A. (IT) 2004-08-24 US claimed
US-20040049031-A1 Method for the synthesis of quinoline derivatives SMITHKLINE BEECHAM CORPORATION 2004-03-11 US claimed
US-6677337-B2 RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS THE PROCTER & GAMBLE COMPANY 2004-01-13 US claimed
US-20030225082-A1 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines PROCTER & GAMBLE COMPANY, THE 2003-12-04 US claimed
CN-1125815-C Method for the synthesis of quinoline derivatives SMITHKLINE BEECHAM CORP (US) 2003-10-29 CN claimed
WO-2003080184-A1 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS THE PROCTER & GAMBLE COMPANY (US) 2003-10-02 WO claimed
US-20020173657-A1 Method for the synthesis of quinoline derivatives SMITHKLINE BEECHAM CORPORATION 2002-11-21 US claimed
US-20020038029-A1 Reacting 3-hydroxy-2-phenylquinoline-4-carboxylic acid, in solvent with riethyl amine, cooling,adding thionyl chloride; adding phenyl propylamine, heating to form (-)-(S)-N( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide SMITHKLINE BEECHAM CORPORATION 2002-03-28 US claimed
US-6335448-B1 NK-3 RECEPTOR ANTAGONISTS ARE USEFUL IN TREATING THE SYMPTOMS OF COPD AND URINARY INCONTINENCE IN MAMMALS. SMITHKLINE BEECHAM CORPORATION 2002-01-01 US claimed
CN-1278796-A Method for the synthesis of quinoline derivatives SMITHKLINE BEECHAM CORP (US) 2001-01-03 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230048657-A1 PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE APP, PSEN1, PSEN2 SLC6A4 466/4885LMNA 1617/4885SCN4A 2899/4885
US-20020038029-A1 Reacting 3-hydroxy-2-phenylquinoline-4-carboxylic acid, in solvent with riethyl amine, cooling,adding thionyl chloride; adding phenyl propylamine, heating to form (-)-(S)-N( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide RPP30, HPD, HRH4 SLC6A4 479/4885LMNA 4118/4885SCN4A 120/4885
US-20020173657-A1 Method for the synthesis of quinoline derivatives NQO2, QARS1, QPCT SLC6A4 2032/4885LMNA 1996/4885SCN4A 1419/4885
US-20030225082-A1 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines IL1B, IL1A, IL1R1 SLC6A4 4829/4885LMNA 2484/4885SCN4A 3331/4885
US-20040049031-A1 Method for the synthesis of quinoline derivatives NQO2, NQO1, CYP3A4 SLC6A4 316/4885LMNA 1836/4885SCN4A 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.